Zinc plus immune therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether adding zinc supplements to standard targeted and immunotherapy improves outcomes for people with advanced liver cancer. Zinc may help the immune system work better against cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and able to give informed consent.
- You have hepatocellular carcinoma (liver cancer) that cannot be removed with surgery, has come back, or has spread to other parts of the body.
- You have not had any prior treatment for liver cancer that affects the whole body (like immunotherapy, targeted therapy, or chemotherapy) or local treatments like surgery, ablation, TACE, or radiation.
- Your liver function is good enough, scored as Child-Pugh class A, and you do not have significant ascites (fluid in the belly), hepatic encephalopathy, or recent liver failure.
- You have at least one measurable tumor that has not been treated locally, and your overall health status is good (ECOG 0 or 1).
- You must be willing to take zinc supplements by mouth and comply with study procedures, and avoid taking other zinc or copper supplements during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This study tests a combination of three drugs (zanzalintinib, durvalumab, and tremelimumab) for people with liver cancer that cannot be removed by surgery and who have not received prior systemic treatment. The goal is to see if this combination can shrink or slow the growth of the cancer.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This study tests a combination of two treatments for advanced liver cancer (hepatocellular carcinoma): a bile acid supplement called tauroursodeoxycholic acid plus an immunotherapy drug (a PD-1/PD-L1 inhibitor) that helps your immune system fight the cancer. The goal is to see if this combination is safe and effective in people who have not yet had any whole-body cancer treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.